focus -WSS

focus

author：hotspot 2025-09-05 18:28:20 - browse：78

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Medicare slashes safety net hospital payments by nearly $1 billion

leisure time

WSS

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Ford recalls 870K F

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Public health communication lessons from Covid

CDC: Cases of alpha

focus

focus

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

What does generative AI mean for health care? We asked experts

Stoke drug shows lower activity against childhood epilepsy

As demand for Covid shots wanes, Moderna seeks its next success

Biden jokes that Republicans may impeach him because inflation is starting to cool down

DIEP, the 'gold standard' of breast reconstruction, is under threat

Late stage cancers on the rise after pandemic delayed screenings

Psychedelics group wrestles with new pharma identity

Behind warning on Apellis’s eye drug lies a conflict of interest

explore

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Timeline: Special counsel's probe into Trump's handling of classified documents

Hospitals, health systems can help patients avoid medical debt

leisure time

hotspot

entertainment

Wikipedia